KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EBT (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of EBT readings, the most recent being $248.0 million for Q4 2025.

  • On a quarterly basis, EBT rose 1054.24% to $248.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $267.4 million, a 407.51% increase, with the full-year FY2025 number at $267.4 million, up 407.51% from a year prior.
  • EBT hit $248.0 million in Q4 2025 for Biocryst Pharmaceuticals, up from $12.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $248.0 million in Q4 2025 to a low of -$74.6 million in Q2 2023.
  • Median EBT over the past 5 years was -$38.4 million (2022), compared with a mean of -$23.6 million.
  • Biggest five-year swings in EBT: tumbled 360.29% in 2022 and later skyrocketed 1054.24% in 2025.
  • Biocryst Pharmaceuticals' EBT stood at -$15.5 million in 2021, then tumbled by 360.29% to -$71.5 million in 2022, then rose by 11.62% to -$63.2 million in 2023, then soared by 58.85% to -$26.0 million in 2024, then skyrocketed by 1054.24% to $248.0 million in 2025.
  • The last three reported values for EBT were $248.0 million (Q4 2025), $12.1 million (Q3 2025), and $6.5 million (Q2 2025) per Business Quant data.